The meta-analysis of 17 RCTs which included approximately 9000 participants showed that anti–TNF-α antibody treatment led to a small but variable effect on 28-day mortality (OR ≈ 0.90, 95% CI 0.83–0.99), which demonstrated greater success in severe sepsis before shock and among patients with high–IL-6 levels [89]. The gene discussed is IL6; the disease is Sepsis.